Skip to main content

Table 1 Baseline characteristics of the study population

From: Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study

Characteristics Total (n = 30)
Clinical characteristics
 Age, year 63.1 (6.6)
 Male Sex, n (%) 24 (80)
 Weight, kg 98.6 (18.0)
 BMI, kg/m2 32.0 (5.2)
 Waist, cm 112.2 (10.9)
 Systolic blood pressure, mmHg 142.7 (19.6)
 Diastolic blood pressure, mmHg 79.7 (10.0)
 Heart rate, bpm 68.6 (10.1)
Risk factors
 Smoker, n (%) 14 (36)
 Hypertension, n (%) 23 (77)
Coronary artery disease
 Previous MI, n (%) 16 (53)
 Previous CABG, n (%) 13 (43)
 Previous PCI, n (%) 16 (53)
 Coronary stenosis, medical therapy only, n (%) 2 (7)
Biochemistry
 Fasting blood glucose, mmol/l 6.4 (1.4)
 HbA1C, % 6.3 (0.5)
 LDL-cholesterol, mmol/l 2.3 (0.7)
 eGFR, ml/min 78.3 (11.5)
Medication
 Beta blockers, n (%) 20 (67)
 Calcium antagonists, n (%) 15 (50)
 ACE-I, ARB, n (%) 20 (67)
 Statins, n (%) 29 (97)
 Ivabradine, n (%) 1 (3)
 Diuretics, n (%) 10 (33)
 Aspirin, n (%) 29 (97)
Pre-study diabetes medication
 Biguanide (metformin), n (%) 12 (40)
 Sulfonylurea, n (%) 1 (3.3)
 Diet and lifestyle therapy only, n (%) 18 (60)
  1. Data are expressed as the mean (SD) or n (%)
  2. ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, bpm beats per minute, CABG coronary artery bypass grafting, HbA1C glycated hemoglobin, MI myocardial infarction, PCI percutaneous coronary intervention, LDL low-density lipoprotein, eGFR estimated glomerular filtration rate